ALPHAHELIX MOL.DIAGN. SK1 (4MB) - Total Liabilities
Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) has total liabilities worth €12.65 Million EUR (≈ $14.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ALPHAHELIX MOL.DIAGN. SK1 - Total Liabilities Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's total liabilities have evolved over time, based on quarterly financial data. See ALPHAHELIX MOL.DIAGN. SK1 (4MB) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Total Liabilities
The table below lists competitors of ALPHAHELIX MOL.DIAGN. SK1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Identillect Technologies Corp
V:ID
|
Canada | CA$1.75 Million |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
Mexico | MX$25.93 Billion |
|
VULTUS AB
F:V06
|
Germany | €5.15 Million |
|
The Alumasc Group plc
LSE:ALU
|
UK | GBX45.48 Million |
|
Asian Television Network International Ltd
V:SAT
|
Canada | CA$6.63 Million |
|
SDI Group plc
LSE:SDI
|
UK | GBX42.38 Million |
|
Anpario Plc
LSE:ANP
|
UK | GBX9.53 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down ALPHAHELIX MOL.DIAGN. SK1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALPHAHELIX MOL.DIAGN. SK1 (4MB) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 27.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALPHAHELIX MOL.DIAGN. SK1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
The table below shows the annual total liabilities of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €13.41 Million ≈ $15.68 Million |
+19.81% |
| 2024-12-31 | €11.20 Million ≈ $13.09 Million |
+29.01% |
| 2023-12-31 | €8.68 Million ≈ $10.15 Million |
-2.63% |
| 2022-12-31 | €8.91 Million ≈ $10.42 Million |
-- |
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to … Read more